Display options
Cite
Waldherr R, Cuzic S, Noronha IL. Pathology of the human mesangium in situ. Clin Investig. 1992;70(9):865-74doi: 10.1007/BF00180757.
Waldherr, R., Cuzic, S., & Noronha, I. L. (1992). Pathology of the human mesangium in situ. The Clinical investigator, 70(9), 865-74. https://doi.org/10.1007/BF00180757
Waldherr, R, et al. "Pathology of the human mesangium in situ." The Clinical investigator vol. 70,9 (1992): 865-74. doi: https://doi.org/10.1007/BF00180757
Waldherr R, Cuzic S, Noronha IL. Pathology of the human mesangium in situ. Clin Investig. 1992 Sep;70(9):865-74. doi: 10.1007/BF00180757. PMID: 1450641.
Copy Download .nbib Format: NLM
Share it on

Clin Investig. 1992 Sep;70(9):865-74. doi: 10.1007/BF00180757.

Pathology of the human mesangium in situ.

The Clinical investigator

R Waldherr, S Cuzic, I L Noronha

Affiliations

  1. Institut für Pathologie, Universität Heidelberg.

PMID: 1450641 DOI: 10.1007/BF00180757

Abstract

Mesangial cells play an important role in the development and progression of human glomerular disease. This article summarizes some important aspects of mesangial properties and behaviour in situ. Intrinsic mesangial cells express alpha-smooth muscle actin and are best characterized as myofibroblasts or glomerular pericytes. The main integrin receptor in the mesangium is the alpha 1 beta 1 integrin. The beta 2 and beta 3 integrins have not been detected. Mesangial cells in situ fail to react with many monoclonal antibodies which stain human mesangial cells in culture, including leukocyte activation antigens. Prominent reactions in glomerular disease are mesangial expansion and progressive glomerular sclerosis, which are preceded by or associated with mesangial cell hypertrophy and/or proliferation. Mesangial enlargement is accompanied by an altered integrin expression and an abnormal composition of extracellular mesangial matrix. From the numerous autocrine and paracrine mediators identified in vitro which stimulate or inhibit mesangial cell growth and extracellular matrix synthesis, up to now only a few factors have been shown to be present in selected human glomerulopathies. These include platelet derived growth factors and platelet derived growth factor receptor beta, transforming growth factors beta, interleukin 1 beta, tumor necrosis factor alpha, and interleukin 6. Further identification of such mediators in situ will improve our understanding of pathological glomerular processes, particularly with respect to the multifunctional properties of the mesangial cell.

Similar articles

References

  1. Lab Invest. 1980 Oct;43(4):373-81 - PubMed
  2. Am J Pathol. 1972 Jan;66(1):97-110 - PubMed
  3. J Pathol. 1991 Mar;163(3):265-72 - PubMed
  4. Kidney Int. 1992 Mar;41(3):530-2 - PubMed
  5. Lab Invest. 1991 Aug;65(2):160-7 - PubMed
  6. Kidney Int. 1989 Jan;35(1):116-24 - PubMed
  7. Lab Invest. 1990 Aug;63(2):189-96 - PubMed
  8. Kidney Int. 1987 May;31(5):1160-6 - PubMed
  9. Virchows Arch A Pathol Anat Histopathol. 1989;415(2):151-9 - PubMed
  10. Kidney Int. 1992 Mar;41(3):524-9 - PubMed
  11. Kidney Int. 1990 Feb;37(2):689-95 - PubMed
  12. Verh Dtsch Ges Pathol. 1989;73:71-82 - PubMed
  13. Kidney Int. 1992 Mar;41(3):590-4 - PubMed
  14. Am J Pathol. 1991 Feb;138(2):313-21 - PubMed
  15. Lab Invest. 1990 May;62(5):616-25 - PubMed
  16. Nephron. 1991;57(3):257-61 - PubMed
  17. Nature. 1990 Jul 26;346(6282):371-4 - PubMed
  18. Am J Pathol. 1990 Sep;137(3):541-52 - PubMed
  19. Lab Invest. 1991 Jul;65(1):61-6 - PubMed
  20. Kidney Int. 1983 Nov;24(5):626-31 - PubMed
  21. J Immunol. 1989 Dec 15;143(12):3949-55 - PubMed
  22. J Lab Clin Med. 1978 Dec;92(6):837-40 - PubMed
  23. Kidney Int. 1989 May;35(5):1203-11 - PubMed
  24. Lab Invest. 1984 Aug;51(2):181-92 - PubMed
  25. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7547-51 - PubMed
  26. Int Arch Allergy Appl Immunol. 1991;94(1-4):23-37 - PubMed
  27. Kidney Int. 1989 Dec;36(6):1099-102 - PubMed
  28. Kidney Int. 1987 Dec;32(6):827-37 - PubMed
  29. J Pediatr. 1982 Nov;101(5):794 - PubMed
  30. J Clin Invest. 1981 Oct;68(4):920-31 - PubMed
  31. Lab Invest. 1991 Sep;65(3):272-9 - PubMed
  32. Kidney Int. 1983 Jul;24(1):1-9 - PubMed
  33. Immunology. 1990 Mar;69(3):391-5 - PubMed
  34. J Cell Biol. 1990 Sep;111(3):1245-54 - PubMed
  35. FASEB J. 1987 Oct;1(4):272-81 - PubMed
  36. Lab Invest. 1991 Apr;64(4):446-56 - PubMed
  37. Am J Physiol. 1990 Nov;259(5 Pt 2):F783-92 - PubMed
  38. Am J Pathol. 1991 Oct;139(4):889-99 - PubMed
  39. Verh Dtsch Ges Pathol. 1989;73:117-23 - PubMed
  40. Kidney Int. 1992 Mar;41(3):671-8 - PubMed
  41. Am J Pathol. 1990 Feb;136(2):369-74 - PubMed
  42. Transplantation. 1983 Apr;35(4):385-90 - PubMed
  43. J Cell Biol. 1982 Aug;94(2):483-8 - PubMed
  44. Kidney Int. 1987 Mar;31(3):820-9 - PubMed
  45. J Clin Invest. 1990 Aug;86(2):453-62 - PubMed
  46. Kidney Int. 1991 Sep;40(3):477-88 - PubMed

MeSH terms

Publication Types

LinkOut - more resources